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localization. It is anticipated that use of such methods will also 
produce improvements in the degree of localization of delivery 
attainable. Finally, achievement of an even distribution of vector 
(prodrug) or gene product (drug) after the vector delivery remains 
a challenge to optimal local delivery. Improvements in this param- 
eter may result from ongoing work with agents to optimize vector 
permeation i to tissues, as well as from complementary mechanical 
approaches. 
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CELL-BASED TRANSFER 
ENDOTHEL IAL  CELLS  FOR SYSTEMIC  AND 
LOCAL GENE THERAPY 
Endothelial cells are excellent target cells for gene therapy and have 
played a prominent role in the development of techniques of 
somatic gene therapy for both vascular and nonvascular diseases. 1 
Endothelial cells regulate blood coagulation and fibrinolysis, vaso- 
motor tone, protein exchange between blood and tissues, anglo- 
genesis, and systemic mmune inflammatory esponses. Endothelial 
cells are also durable cells whose half-lives are measured inyears and 
thus are one of the longest-lived cells in the human body. Two 
additional characteristics make endothelial cells ideal target cells for 
somatic gene therapy. One characteristic is that endothelial cells are 
pluripotent, hat is, their phenotypic expression is regulated in part 
by their local environment. This enhances their capacity for 
successful transplantation to different locations within the circula- 
tory system. Second, endothelial cells are located at the blood- 
tissue interface and thus they provide aunique mechanism by which 
to deliver a recombinant protein to achieve an autoctine, paracrine, 
or endocrine ffect. 
Two basic strategies are used in somatic gene therapy. One is ex 
vivo gene therapy, in which specific target cells are harvested from 
the patienf, transduced ex vivo, and transplanted back into the 
patient. A variety of somatic ells have been examined for use in ex 
vivo gene therapy, including lymphocytes, endothefial cells, myo- 
cytes, fibroblasts, hematopoietic stern cells, and respiratory airway 
epithelial cells. The principle advantage of ex vivo gene therapy 
is that a population of pure, genetically modified target cells can 
be developed. In addition, none of the other tissues of the patient 
are exposed to any of the potentially harmful effects of the gene 
transfer technique. The major disadvantage is that this technique 
requires at least two procedures, one in which the target cells are 
harvested and undergo genetic modification, and a second pro- 
cedure to transplant the autologous, genetically modified cells 
back into the patient. 
A second form of somatic gene therapy is direct gene transfer 
in vivo, in which the transgene is transferred into the target cell in 
vivo. In this technique one can avoid the complications associated 
with the harvest as well as the transplantation cells back into the 
host. A major impediment to direct gene transfer is the availability 
of techniques of gene transfer that result in efficient and durable 
transgene expression i  vivo. 
In June 1989, two landmark studies were published that 
demonstrated that endothelial cells that underwent gene transfer ex 
vivo could be successfully transplanted into a vessel wall in vivo. In 
one study, Nabel and colleagues 2 uccessfully transplanted geneti- 
cally modified endothelial cells into the arterial wall of a pig. In this 
study, the transduced cells were shown to survive and express 
recombinant protein for as many as 4 weeks after transplantation. 
In a second study, Wilson and colleagues 3 transplanted genetically 
modified endothelial cells onto the surfaces of synthetic vascular 
grafts. The grafts seeded with transduced endothellum were 
subsequently placed as carotid interposition grafts into a canine 
model. This study established that genetically modified cells could 
be seeded successfully onto synthetic vascular grafts and that 
recombinant gene expression was confirmed in vivo. 
Because capillaries constitute more than 80% of the surface area 
of the circulatory system, they are a logical recipient site to 
transplant genetically modified endothelial cells in vivo. However, 
transplantation f transduced endothelial cells into the capillary 
bed is problematic. Although the endothelium of muscular arteries 
can be denuded and reseeded successfully, denudation of capillary 
endothelium as a means of facilitating cell transplantation might 
disrupt important normal microcirculatory hemodynamics and 
functions, as well as initiate an unwanted vessel wall injury response. 
Nonetheless, capillaries are a logical site for recombinant protein 
production to achieve either a regional or systemic therapeutic 
effect. 
We have targeted the capillary bed of skeletal muscle because it
possesses a high-density, accessible capillary network and is rela- 
tively resistant to ischemic injury. Furthermore, skeletal muscle, 
similar to the liver, is capable of regeneration after a variety of 
injuries. We first undertook a series of in vitro experiments o 
circumvent the need for denudation of capillary endothelium. We 
tested the hypothesis that activation of confluent endothelial cell 
monolayers in vitro by cytokines would promote adhesion and 
incorporation of endothefial cells seeded onto these monolayers. 
However, in the course of these experiments we identified a 
previously unrecognized capacity of endothelial cells to adhere and 
incorporate spontaneously into the untreated confluent endothelial 
cell monolayers in vitro. 4 In a second series of experiments, we 
documented that this property of spontaneous endothelial cell 
adhesion and incorporation i to preexisting monolayers can also 
occur in vivo and provide a strategy for somatic gene therapy. 4 
Transmission electron microscopy reveals that certain transduced 
endothelial cells were incorporated into the capillary wall, whereas 
others remained viable within the capillary lumen, forming multiple 
areas of local electron-dense communications with the underlying 
endothellum of the capillary wall. 
To promote greater incorporation of transduced endothefium, 
we evaluated two different strategies to induce angiogenesis in the 
capillary bed of skeletal muscle. The myotoxic anesthetic lidocaine 
promotes rapid degeneration of skeletal muscle sarcoplasm, fol- 
lowed by satellite cell activation and regeneration of the muscle 
fiber. A second approach to the induction of angiogenesis is to 
administer an agent that only induces angiogenesis. One such 
example is basic fibroblast growth factor. We characterized the 
angiogenic potential of  these agents in the tibialls anterior muscle 
of Sprague-Dawley rats. At all timepoints after injection, lidocalne 
treatment evoked asubstantially higher proliferative response than 
basic fibroblast growth factor, and more importantly the anglo- 
genie response was durable. Using this model oflidocaine-induced 
muscle regeneration and angiogenesis, we documented enhanced 
adhesion and incorporation of transduced endothelium into the 
capillary wall. 
Considerable progress has been made in the development of
experimental models of direct gene transfer to the arterial wall in 
vivo. The impetus for this work has been due to the recognition of 
the complexi W of ex vivo gene transfer and subsequent reimplan- 
tation of the transduced cells, as well as to advances in techniques 
of gene transfer. We have modified our animal model to achieve 
vascular isolation of the hind limb. In this regard, we have evaluated 
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both direct retroviral gene transfer as well as adenoviral gene 
transfer. 
During vascular isolation, we first injected a concentrated 
solution ofa retroviral vector containing human heat-stable alkaline 
phosphatase into skeletal muscle 4 days after lidocaine-induced 
regeneration and angiogenesis. In these experiments we docu- 
mented a substantially higher expression of recombinant protein 
than that achieved using the previously described technique of 
cell-mediated gene therapy. Recombinant gene expression was 
observed in both the muscle and capillary endothelium. 
This technique of vascular isolation of the hind limb has also 
been used to test the transduction efficiency of adenoviral vectors. 
Current gene therapy strategies using adenoviralvectors targeted to 
the lung or liver have been complicated by an inflammatory 
response and an associated tissue injury. We hypothesized that 
adenoviral transduction ofrat skeletal muscle capillary bed during 
vascular isolation would produce gene transfer sufficient to achieve 
systemic levels of a recombinant protein without tissue injury. 
During vascular isolation, rats received a replicationqncompetent 
adenovirus (Ad) encoding for either the marker gene, human 
placental alkaline phosphatase (hpAP) or interleukin-1 receptor 
antagonist (IL-lra), an antagonist oflL-1 mediated isease. Gene 
transfer over a 109 × 1012 particle/mL range to the gastrocnemius 
capillary endothelium and muscle fibers was highly efficient and 
titer dependent, reaching a maximum transduction rate in these 
tissues of 71% + 7% and 25% _+ 5%, respectively, 5 days after gene 
transfer. Adenoviral-induced inflammation i skeletal muscle was 
not observed, and distant organ transfer was minimal or absent. 
Gastrocnemius muscle from rats given Ad-IL-lra had 241 i 66 pg 
IL- l ra/mg protein, whereas the Ad-hpAp negative control had 
35 _+ 14 pg ILq-ra /mg protein. More importantly-, in the Ad-IL- 
lra transduced rats, a serum level of 185 _+ 20 pg/mL IL-lra was 
documented. Athymic rats given Ad-IL-lra had serum levels of 
4:93 _+ 62 pg/mL IL-lra 14 days after transduction, an IL-lra was 
detected for up to 98 days. Serum from Ad-IL-lra athymic rats 
significantly inhibited IL-1 [3-induced (1 ng/mL) PGE 2 produc- 
tion from cultured endothelial cells by 82% -+ 2%. Thus this gene 
transfer strategy results in substantial transduction ofendothelinm 
and muscle fibers, sufficient o achieve pharmacologic levels of 
IL-lra, without evidence of tissue injury. 
We believe the capillary bed of skeletal muscle continues to 
hold considerable promise as a technique of somatic gene therapy 
to deliver ecombinant proteins to the systemic irculation, such as 
human factor VIII or IX deficiency in hemophiliacs or for the 
purposes of treating vascular diseases uch as the induction of 
angiogenesis in a chronic ischemic limb. 
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CELL-BASED GENE TRANFER 
IN  B IOMATERIALS  
A number of biomaterials in a wide variety of configurations and 
materials have been adapted to gene transfer technology. Special 
needs uch as immunoisolation, size of the gene product molecule, 
biodegradability, cell carrying capacity, and durability both of the 
material and gene expression determine physical characteristics. 
Hollow fibers, pillows, and microspheres are commonly used. With 
a single gene the null mutant apolipoprotein deficicnt (knockout) 
mouse converts aspecies highly resistant to atherosclerosis to one 
that is highly susceptible. This mutant model develops evere 
atherosclerosis on a normal diet. The lesions closely resemble 
human lesions. 
Using a plasmid containing the eDNA encoding apo E, 
fibroblasts or mouse mammary tumor cells, and two constructs: (1) 
retroviral vectors based on LNL6 retroviral vector (MoMLV), the 
long terminal repeat promoter (LTR) and one of several enhancers; 
or (2) a recombinant bovine paplllomavirus expression vector 
containing a mouse metallothionein I promoter, the human 
metallothionein IA gene and, in both, the human apo E gene, we 
have been able to transfect the fibroblasts and mouse mammary 
tumor cells, load the cells into the devices named above, and obtain 
apo E expression both in tissue culture and in the plasma of mice 
into the cell-loaded evices implanted. Coincident with the appear- 
ance of apo E in the mouse plasma was a substantial reduction in 
serum cholesterol and triglycerides. Inhibition of atherosderosis 
throughout the aorta of the apo E-deficient mouse was prominent 
in the treated mouse compared with the untreated control, (28% vs 
69%, respectively, based on planimetric measurement of he lesions 
visible on the surface of the aortas). 
This is an excellent animal model in which to study athero- 
genesis and its progression and regression. As far as therapeutic 
potential, there are several obstacles and pitfalls, including a low 
level of transfected gene expression, eventual loss of gene expres- 
sion, need for continuing replication of the transfected cells, escape 
of implanted cells from the device, induction of host viremia, and 
unpredictable consequences of random gene insertion. 
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